Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.
Lymphomas represent a wide group of heterogenic diseases with different biological and clinical behavior. The underlying microenvironment-specific composition seems to play an essential role in this scenario, harboring the ability to develop successful immune responses or, on the contrary, leading to immune evasion and even promotion of tumor growth. Depending on surrounding lymphoid infiltrates, lymphomas may have different prognosis. Moreover, recent evidences have emerged that confer a significant impact of main lymphoma's treatment over microenvironment, with clinical consequences. In this review, we summarize these concepts from a pathological and clinical perspective. Also, the state of the art of lymphoma's anti-idiotype vaccine development is revised, highlighting the situations where this strategy has proven to be successful and eventual clues to obtain better results in the future.
Alvaro
Tomás
T
Pathology Department, Hospital de Tortosa Verge de la Cinta, 41300 Tortosa, Spain.
de la Cruz-Merino
Luis
L
Henao-Carrasco
Fernando
F
Villar Rodríguez
José Luis
JL
Vicente Baz
David
D
Codes Manuel de Villena
Manuel
M
Provencio
Mariano
M
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D059016:Tumor Microenvironment
D000970:Antineoplastic Agents
Eur J Haematol Suppl. 2007 Jan;(67):5-14
17206982
Clin Cancer Res. 2008 Feb 1;14(3):685-91
18245527
Hematology Am Soc Hematol Educ Program. 2007;:243-9
18024636
J Clin Invest. 2006 Oct;116(10):2777-90
17016559
Nature. 2000 Apr 27;404(6781):999-1003
10801129
Blood. 2006 Jan 15;107(2):628-36
16179369
Br J Cancer. 2006 Jan 30;94(2):259-67
16404427
FASEB J. 2004 Nov;18(14):1716-8
15345697
Lancet Oncol. 2009 Jul;10(7):718-26
19573801
Blood. 2002 Feb 1;99(3):1038-43
11807010
Nat Med. 2007 Jan;13(1):54-61
17187072
Oncogene. 2003 Nov 24;22(53):8543-67
14634618
Oncologist. 1999;4(2):106-11
10337380
N Engl J Med. 2006 Jun 8;354(23):2503-4
16760453
Nat Med. 2000 Apr;6(4):443-6
10742152
J Immunol. 1987 Feb 15;138(4):1289-96
3492546
Oncologist. 2008 Dec;13(12):1246-54
19056856
J Clin Oncol. 2007 Apr 1;25(10):1289-91; author reply 1291-2
17401023
J Clin Oncol. 2002 Jun 15;20(12):2904-5; author reply 2905
12065568
Leukemia. 2008 Jan;22(1):49-58
17914412
Annu Rev Pathol. 2006;1:119-50
18039110
Science. 2003 Feb 14;299(5609):1057-61
12522256
Am J Clin Pathol. 1988 Sep;90(3):257-61
2970792
Blood. 2005 Jul 1;106(1):338-44
15769894
Nat Rev Cancer. 2009 Sep;9(9):675-81
19701243
J Clin Oncol. 2009 Jan 1;27(1):154-5
19029411
Clin Cancer Res. 2010 Jan 15;16(2):637-50
20068089
Ann Hematol. 2005 Oct;84(10):661-6
15875183
J Clin Oncol. 2000 Apr;18(8):1614-21
10764421
Blood. 2003 Feb 15;101(4):1220-35
12393483
J Immunother. 2007 Jan;30(1):64-74
17198084
Expert Rev Vaccines. 2006 Jun;5(3):381-94
16827622
J Clin Invest. 2004 May;113(10):1498-510
15146248
Mutat Res. 2006 May 11;597(1-2):119-32
16438994
Clin Cancer Res. 2009 Nov 1;15(21):6582-94
19861448
Clin Cancer Res. 2007 Jul 1;13(13):3776-82
17606707
N Engl J Med. 2004 Nov 18;351(21):2159-69
15548776
Haematologica. 2008 Feb;93(2):193-200
18223287
Blood. 2005 Mar 1;105(5):1851-61
15550490
Haematologica. 2006 Dec;91(12):1605-12
17145596
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10972-7
8855293
Immunol Rev. 2007 Dec;220:47-59
17979839
Blood. 2008 Sep 1;112(5):1557-69
18725574
J Clin Oncol. 2006 Dec 1;24(34):5350-7
17135637
Blood. 2002 Feb 15;99(4):1314-9
11830481
Curr Opin Immunol. 2008 Oct;20(5):545-57
18573339
Cell. 2006 Jan 27;124(2):263-6
16439202
J Clin Oncol. 2008 Jun 1;26(16):2725-31
18427151
N Engl J Med. 2000 Jul 6;343(1):37-49
10882768
N Engl J Med. 2008 Nov 27;359(22):2313-23
19038878
J Leukoc Biol. 1999 Aug;66(2):345-9
10449179
Blood. 1999 Apr 15;93(8):2688-96
10194449
Oncologist. 2007;12 Suppl 2:22-6
18039636
Leukemia. 2004 Mar;18(3):589-96
14712286
J Clin Oncol. 2003 Jun 15;21(12):2415-32
12805342
Br J Haematol. 2009 May;145(4):468-80
19344401
Anticancer Drugs. 2002 Nov;13 Suppl 2:S3-10
12710585
Haematologica. 2009 Jan;94(1):70-7
19059937
J Immunol. 1990 Apr 1;144(7):2550-7
1969451
Ann Oncol. 2009 Oct;20(10):1688-96
19542249
Nat Rev Cancer. 2005 May;5(5):397-405
15864281
Nature. 2005 Dec 8;438(7069):820-7
16341007
N Engl J Med. 2001 Apr 5;344(14):1058-66
11287977
Ann Oncol. 1998;9 Suppl 5:S21-4
9926233
Cancer Immunol Immunother. 2007 Nov;56(11):1687-700
17571260
Ann Hematol. 2005 Aug;84(8):510-6
15834569
Leuk Lymphoma. 2005 Nov;46(11):1581-91
16236613
J Clin Oncol. 2008 Nov 10;26(32):5156-64
18854568
Blood. 2004 Jun 1;103(11):4251-8
14976040
Proc Natl Acad Sci U S A. 1983 Jun;80(12):3816-20
6602341
J Clin Oncol. 2001 Feb 1;19(3):720-6
11157023
Cell. 1995 Apr 7;81(1):9-12
7536631
Haematologica. 2003 Sep;88(9):1002-12
12969808
Cancer Res. 2008 Jan 15;68(2):450-6
18199539
Science. 2004 May 14;304(5673):1014-8
15143282
J Clin Pathol. 2003 Jun;56(6):423-5
12783967
Nature. 2005 Aug 25;436(7054):1186-90
15995699
Crit Rev Oncol Hematol. 2009 May;70(2):103-13
18996025
Trends Immunol. 2002 Nov;23(11):549-55
12401408
J Immunol. 2007 Jun 1;178(11):6840-8
17513732
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5866-73
14676108
Cancer Immunol Immunother. 2001 Dec;50(10):566-8
11776379
Cancer Res. 2003 Aug 1;63(15):4516-20
12907625
Cancer Control. 2000 Nov-Dec;7(6):513-22
11088060
Nat Med. 2007 Sep;13(9):1050-9
17704786
Blood. 2007 Jun 1;109(11):4952-63
17284527
Curr Opin Immunol. 2008 Oct;20(5):504-11
18573340
Blood. 2006 Nov 1;108(9):2957-64
16825494
Nat Med. 2005 Sep;11(9):986-91
16116429
Blood. 2002 Jun 15;99(12):4283-97
12036854
J Transl Med. 2005 Feb 08;3(1):8
15698481
Br J Cancer. 2002 Jul 1;87(1):21-7
12085250
J Cell Biochem. 2007 Jul 1;101(4):805-15
17226777
J Exp Med. 2010 Mar 15;207(3):637-50
20156971
Blood. 2009 Oct 15;114(16):3367-75
19636060
Blood. 2009 Oct 1;114(14):2936-44
19671921
Clin Cancer Res. 2005 Feb 15;11(4):1467-73
15746048
Crit Rev Oncol Hematol. 2009 Mar;69(3):187-98
18675551
Cell. 2000 Jan 7;100(1):57-70
10647931
Apoptosis. 2006 Jun;11(6):1013-23
16544097
Haematologica. 2009 Jan;94(1):16-21
19118376
Cancer Sci. 2007 Sep;98(9):1368-72
17640305
Expert Opin Biol Ther. 2009 Jan;9(1):21-8
19063690
N Engl J Med. 1992 Oct 22;327(17):1209-15
1406793
Oncologist. 2008 Sep;13(9):954-66
18779537
Cancer Res. 2008 Oct 1;68(19):8122-6
18829571
Blood. 2005 Jan 1;105(1):301-7
15345589
Br Med Bull. 2002;62:149-62
12176857
J Immunol. 2008 Sep 1;181(5):3099-107
18713980
Expert Rev Vaccines. 2009 Jan;8(1):43-50
19093772
Semin Cancer Biol. 2006 Feb;16(1):38-52
16139507
Cancer Res. 2004 Mar 15;64(6):2205-11
15026364
J Clin Invest. 2007 May;117(5):1167-74
17476346
Cell Death Differ. 2007 Jul;14(7):1237-43
17431418
Blood. 2004 Mar 1;103(5):1755-62
14604957
Blood. 2005 Sep 15;106(6):2169-74
15933054
Leukemia. 2001 Mar;15(3):458-64
11237071
J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301
16985248
Cell Death Differ. 2007 Oct;14(10):1848-50
17657249
J Clin Oncol. 2009 Jun 20;27(18):3036-43
19414675
Cancer Immunol Immunother. 2004 Feb;53(2):73-8
14610619
J Clin Oncol. 2005 Dec 10;23(35):8950-8
16061910
J Clin Invest. 2008 Jun;118(6):1991-2001
18523649